CPC Scientific Showcases Peptide and Oligonucleotide CRDMO Leadership at Major Q1 2026 Pharma Events

Rocklin, CA – CPC Scientific Inc., a global Contract Research, Development, and Manufacturing Organization (CRDMO) specializing in peptides and oligonucleotides, and a subsidiary of Medtide Inc., will participate in three major pharma industry events across Europe and North America in the first quarter of 2026.

CPC Scientific teams are accepting appointment bookings for face-to-face meetings at all three events (see Resources).

RNA Leaders Europe 2026: Oligonucleotide and POC Capabilities on Display

At the three-day RNA Leaders Europe conference, opening March 17 in Vienna, CPC Scientific will join the conversation on RNA innovation, including therapeutics, sequencing, and RNA-based technologies.

Exhibiting from Booth 7 at the Austria Center, CPC Scientific will be represented at the event by Vice President of Oligonucleotide Business Development Sheri Ambriz and Manager of Business Development for Europe, Clàudia Badia i Lopez. The team will present CPC Scientific’s oligonucleotide and peptide capabilities and discuss peptide, oligonucleotide, and peptide–oligonucleotide conjugate (POC) API projects.

DCAT Week 2026: GMP Peptide and Oligonucleotide Manufacturing Expertise

A week later, CPC Scientific will be represented by a senior leadership delegation at DCAT Week,  the premier pharma and biotech industry expo and networking event organised by America’s Drug, Chemical & Associated Technologies Association and opening March 23 in New York City.

The CPC Team, including President Theresa Cheng, Senior Vice President of Strategic Portfolio Tim Nieters, and Director of International Business Development Diego Silva, will host meetings at Suite 3712 of the Lotte New York Palace to discuss GMP peptide and oligonucleotide manufacturing and synthetic API scale-up projects.

NextGen Biomed London: Accelerating Commercial-Scale Peptide Development

At almost the same time, Sheri Ambriz and Clàudia Badia i Lopez will be headed for London to join Senior Manager of Business Development for Europe Joseph Denby in representing CPC Scientific at the two-day NextGen Biomed conference, opening March 24.

The trio will host discussions on peptide and oligonucleotide-based API projects from Booth 40 in the Exhibition Zone at the QEII Centre, as part of the event mission to provide a knowledge-sharing platform for research leaders, product developers and manufacturing teams looking to accelerate commercial scale development of innovative biotherapeutics.

“Going with the Compound” — Scalable Peptide and GLP-1 Manufacturing Strategy

Across all three events, CPC Scientific will highlight its “going with the compound” strategy –  aligning capacity expansion, technical investment, and regulatory infrastructure with evolving customer pipelines and market demand.

A significant proportion of peptide and oligonucleotide programs currently in clinical development are expected to transition to commercial production within the next three to five years. This shift is being driven by:

• Anticipated commercialization of multiple late-stage peptide programs
• Sustained global demand for GLP-1 and obesity therapeutics
• Expanding opportunities in peptide generics as key patents expire across major markets

CPC Scientific is positioned to support this transition with scalable, inspection-ready infrastructure and integrated CRDMO services offering consistent advantages in quality, efficiency, and supply reliability:

• Comprehensive lifecycle support: From discovery and preclinical research through Phase I–III clinical development to commercial GMP manufacturing, minimizing hand-offs and operational risk.
• Regulatory excellence: Nearly 25 years of expertise, a >99.95% new-molecule synthesis success rate, five FDA on-site GMP inspections, inspections by EMA, MFDS, and TGA, and nine NMPA inspections in the past five years.
• Scale and innovation: Advanced peptide production technologies and metric-ton-scale GMP API capacity, with annual peptide API output exceeding 1,000 kg.
• Global trust: Long-term partnerships with pharmaceutical and biotech companies in 50+ countries, supporting both NCE and generic peptide development.
• GLP-1 leadership: Recognized expertise in oral and injectable GLP-1 and obesity programs – among the fastest-growing segments of the global peptide market.

About CPC Scientific, Inc.

With nearly 25 years of experience, CPC Scientific is a globally recognized Contract Research, Development, and Manufacturing Organization (CRDMO) that specializes in synthetic GMP peptides, oligonucleotides, and peptide-oligonucleotide conjugates (POCs), while offering a full range of research-grade custom and catalog products. Our integrated service model is designed to support partners through the most critical phases of drug development, with a particular focus on late-phase development, large-scale manufacturing, and commercial production. From initial discovery to full commercialization, we provide the expertise and robust infrastructure to accelerate peptide and oligonucleotide programs to success, backed by metric-ton scale GMP manufacturing and an annual production capacity exceeding 1,000 kg.

CPC Scientific meticulously follows FDA and ICH guidelines for CGMP manufacturing, and we provide complete support for your IND, NDA, and BLA filings in the USA and all international filings and required regulatory support for your active pharmaceutical ingredients (APIs). Our New Chemical Entity (NCE) development program involves process development, process validation, analytical method development, method validation, stability studies, regulatory support, and assistance preparing regulatory documents. We also have flexibility, pre-qualified workspace, and robust supply chain to incorporate new projects into our pipeline rapidly. We understand that delivery time is critical to your project’s success, and we have the capacity and flexibility to accept new projects and initiate production sooner than many leading CDMOs.

With a USA facility in Rocklin, near Sacramento, California, CPC Scientific is a subsidiary of Medtide Inc., which officially listed on the main board of the Hong Kong Stock Exchange in 2025.

Learn more at: https://cpcscientific.com

Resources

Click on CPC Scientific News and Articles to see latest News & Events.
Meet CPC Scientific at RNA Leaders Europe Congress, Vienna
Meet CPC Scientific at DCAT Week, NYC
Meet CPC Scientific at NextGen Biomed, London